Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh

Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka

Hygene Ag

Biopharm Gesellschaft Zur Biotechnologischen Entwicklung

Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh

Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharamaka Mbh

Rolf Bechtold

Jens Pohl

Helge Neidhardt

Gertrud Hötten

Michael Paulista

Gertrud H&ouml;tten

Klaus Unsicker

Michael Kruse

Gertrud Hotten

Jun Honda

Hidetoshi Andou

Shunjiro Sugimoto

The present invention concerns improved osteoinductive materials comprising matrix materials and morphogenetic proteins, wherein depending on the subject matter the proteins may be dimeric or monomeric proteins. The osteoinductive materials according to the present invention have improved properties. The invention further concerns methods for producing the respective improved osteoinductive materials.

Method of treating diseases or abnormal conditions of periodontal or dental tissues with GDF5

A process for preparing a purified refolded monomer or dimer of a bone-derived factor, which comprises subjecting an inclusion body of a bone-derived factor produced by genetic engineering to the following steps a) to c) in sequence:

Process for preparing purified active monomer of bone-derived factor

The present invention concerns the use of biologically active MP52 or/and MP121 for the treatment and prevention of diseases of the nervous system or/and for the treatment of neuropathological situations which are caused by ageing of the nervous system. A pharmaceutical agent according to the invention for the treatment and prevention of diseases of the nervous system or/and for treating neuropathological situations which are caused by ageing of the nervous system therefore contains biologically active MP52 or/and MP121 as the active substance.

Use of MP52 or MP121 for the treatment and prevention of diseases of the nervous system

The present invention is concerned with proteins selected from the members of the TGF-&#x3b2; superfamily, which are monomeric due to substitution or deletion of a cysteine which is responsible for dimer formation. The invention is also concerned with nucleic acids, encoding such monomeric proteins, vectors or host cells containing the nucleic acids as well as with pharmaceutical compositions comprising the proteins or nucleic acids encoding the proteins. The compositions can be applied advantageously for all indications for which the respective dimeric proteins are useful.

Monomeric protein of the TGF-&#x3b2; family

The present invention concerns improved osteoinductive materials comprising matrix materials and morphogenetic roteins, wherein depending on the subject matter the proteins may be dimeric or monomeric proteins. The osteoinductive materials according to the present invention have improved properties. The invention further concerns methods for producing the respective improved osteoinductive materials.

Osteoinductive materials

The invention provides DNA sequences encoding novel members of the TGF-&#x3b2; family of proteins. The TGF-&#x3b2; family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also describes the isolation of the above-mentioned DNA sequences, the expression of the encoded proteins, the production of said proteins and pharmaceutical compositions containing said proteins.

Growth/differentiation factor of the TGF-&#x3b2; family

The invention relates to an antibody or antibody fragment which specifically binds to a protein of the TGF-&#x3b2; family. The invention also relates to a kit for detecting a protein of the TGF-&#x3b2; family which comprises the antibody or antibody fragment. Finally, the invention relates to method for detecting a protein of the TGF-&#x3b2; family which uses the antibody or antibody fragment.

Antibodies to a growth/differentiation factor of the TGF-&#x3b2; family

The invention concerns a protein of the TGF-&#x3b2; family, the DNA coding therefor and a pharmaceutical composition containing such protein.

MP121, a growth/differentiation factor of the TGF-&#x3b2; family

The present invention is concerned with proteins selected from the members of the TGF-&#x3b2; superfamily, which are monomeric due to substitution or deletion of a cystein which is responsible for dimer formation. The invention is also concerned with nucleic acids, encoding such monomeric proteins, vectors or host cells containing the nucleic acids as well as with pharmaceutical compositions comprising the proteins or nucleic acids encoding the proteins. The pharmaceutical compositions can be applied advantageously for all indications for which the respective dimeric proteins are useful.

The present invention relates to a pharmaceutical composition having neurotrophic activity, comprising a biologically active amount of at least two cytokines, wherein at least one of said cytokines is BMP, GDF, TGF-&bgr; or GDNF.

Cytokines having neurotrophic activity

Use of MP52 or MP121 for treating and preventing diseases of the nervous system

The invention provides DNA sequences encoding novel members of the TGF-&bgr; family of proteins. The TGF-&bgr; family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also describes the isolation of the above-mentioned DNA sequences, the expression of the encoded proteins, the production of said proteins and pharmaceutical compositions containing said proteins.

DNA sequences encoding growth/differentiation

The invention concerns a protein of the TGF-&bgr; family, the DNA coding therefor and a pharmaceutical composition containing such protein.

Method of treatment with growth/differentiation factors of the TGF-&bgr; family

The invention provides DNA sequences encoding novel members of the TGF-.beta. family of proteins. The TGF-.beta. family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also describes the isolation of the above-mentioned DNA sequences, the expression of the encoded proteins, the production of the proteins and pharmaceutical compositions containing the proteins.

Growth/differentiation factors of the TGF-.beta. family

The invention concerns a protein of the TGF-.beta. family, the DNA coding therefor and a pharmaceutical composition containing such a protein.

Growing community of inventors

Heidelberg, Germany

Rolf Bechtold